SPY306.28+0.73 0.24%
DIA256.75+1.48 0.58%
IXIC9,515.46-36.59 -0.38%

Omeros To Present Narsoplimab Pivotal Trial Data At European Hematology Association Annual Congress Jun. 11-14

Omeros Corporation (NASDAQ:OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the

Benzinga · 05/14/2020 13:07

Omeros Corporation (NASDAQ:OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually.

The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy, will be delivered by Alessandro Rambaldi, M.D., Professor of Hematology at the University of Milan and Head of the Hematology and Bone Marrow Transplant Unit at ASST Papa Giovanni XXIII in Bergamo, Italy. Selected by EHA for a podium presentation, it will include efficacy data not previously presented.